Top Performing Drug – Trikafta/Kaftrio (May Edition)

Shots:In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have covered Trikafta/Kaftrio as the top-performing drug of the monthTrikafta is a combination of ivacaftor, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis in pediatric patients who have at least one…

BySenior EditorMay 24, 2023

INSIGHTS+

Top Performing Drug – Dupixent (April Edition)

Shots:In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have selected Dupixent and prepared a curated analysis report for our readersDupixent is an interleukin-4 receptor alpha antagonist used for the treatment of multiple indications including atopic dermatitis, asthma, eosinophilic esophagitis, etc.PharmaShots…

BySenior EditorApril 26, 2023

THOUGHTSPOT

ILAP and its nuance vs PRIME since BREXIT

IntroductionPRIME (PRIority MEdicines)EMA launched PRIME on March 07, 2016, to support the development of medicines targeting unmet medical needs. The scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients faster.PRIME builds on the…

BySenior EditorSeptember 13, 2022

VIEWPOINTS

PharmaShots Interview: BoneHealth Technologies’ Laura Yecies Shares Insights on OsteoBoost Vibration Belt

In a recent interview with PharmaShots, Laura Yecies, CEO of BoneHealth Technologies shared her views on OsteoBoost Vibration Belt that has been granted 'Breakthrough Device' designation by the US FDAShots:OsteoBoost receives the US FDA's BDD to reduce the risk of osteoporosis. It uses vibration technology that delivers mechanical stimulation to the hips & spine at…

BySenior EditorFebruary 2, 2021

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2019

The first quarter of 2019 has marked with major events in the pharma & biotech industries. We have gathered the key highlights of the quarter, which was starting with the blockbuster news, where Celgene had acquired BMS for $74B. Moving to the next news, acquisition of Loxo Oncology for $8B, in addition to Spark Therapeutics…

BySenior EditorAugust 4, 2019

Top Performing Drug – Trikafta/Kaftrio (May Edition)

Top Performing Drug – Dupixent (April Edition)

ILAP and its nuance vs PRIME since BREXIT

PharmaShots Interview: BoneHealth Technologies’ Laura Yecies Shares Insights on OsteoBoost Vibration Belt

PharmaShots’ Key Highlights of First Quarter 2019

Contact US

OUR INFORMATION

FOLLOW US